Abstract 617P
Background
Primary tumor location (PTL) has a confirmed prognostic and predictive effect in colorectal cancer first-line therapy, but its effect during the refractory stage is uncertain.
Methods
Clinical data of patients diagnosed with mCRC who received regorafenib (R) and/or trifluridine/tipiracil (T) between July 2012 and March 2022, were collected from 13 Italian cancer institutes retrospectively. Patients were divided into two groups based on whether they presented right (RCC) or left colon cancer (LCC). Our aim was to evaluate the impact of PTL on overall survival (OS), progression-free survival (PFS), and disease control rate (DCR) in R or T treatment groups in a real-world setting.
Results
866 patients were included. Of these, 146 (16.8%) received T followed by R (T/R), 116 (13.3%) the reverse sequence (R/T), 325 (37.5%) received T alone, and 279 (32.5%) R alone. M/F=504/362; median age was 68 (30-87); median duration of follow-up was 7.2 months. We focused on patients who were sequentially treated with T and R and with the reverse sequence. Among 262 patients, we identified 52 RCC and 94 LCC in the T/R group, compared to 34 RCC and 82 LCC of the reverse sequence. In LCC patients, we found an OS advantage, with a median of 16.8 months in the R/T group vs. 14.7 months in the T/R group (p=0,0569). PFS was statistically significantly longer for the LCC patients who received the R/T sequence (11.7 vs. 9.1 months of the reverse sequence) (p=0,0022). PTL had no effect on disease control rate: we identified the best DCR (34.8%) in LCC patients in both T/R and R/T sequences (p=0.4904).
Conclusions
In our real-world analysis, PTL appears to have a prognostic impact in patients with refractory metastatic colorectal cancer who have received R and T in a sequential way. In fact, treatment with the sequence R/T seemed to us significantly correlated with better outcomes in terms of OS and PFS in patients with left-sided primary cancer. In terms of DCR, we cannot state that PTL is a predictive factor. We advise conducting additional research with sequential R and T treatment. Prospective clinical investigations, we believe, are required in this context.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
C. Signorelli.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
611P - SHR-1701 in combination with BP102 and XELOX as first-line (1L) treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Data from a phase II/III study
Presenter: Rui-Hua Xu
Session: Poster session 10
612P - Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
Presenter: fuxiang zhou
Session: Poster session 10
613P - Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Gerald Prager
Session: Poster session 10
614P - Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Josep Tabernero
Session: Poster session 10
615P - The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer
Presenter: Satoshi Yuki
Session: Poster session 10
616P - Sequential treatment with regorafenib (REG) and trifluridine/tipiracil (TAS) +/- bevacizumab (Bev) in refractory metastatic colorectal cancer (mCRC) in community clinical practice in the USA
Presenter: Tanios Bekaii-Saab
Session: Poster session 10
618P - Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer
Presenter: Tae Won Kim
Session: Poster session 10
619P - Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study
Presenter: Guy Ungerechts
Session: Poster session 10
620P - A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC): ABACO trial initial molecular data
Presenter: Giulia Martini
Session: Poster session 10
621P - The systemic proteome of consensus molecular subtypes from patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial
Presenter: Alexej Ballhausen
Session: Poster session 10